MiR-125b controls apoptosis and temozolomide resistance by targeting TNFAIP3 and NKIRAS2 in glioblastomas

Cell Death and Disease

Volumn 5, Issue 6, 2014, Pages

  Haemmig, S ^a   Baumgartner, U ^a   Gluck A ^a,c   Zbinden, S ^a   Tschan, M P ^a   Kappeler, A ^a   Mariani, L ^b   Vajtai, I ^a   Vassella, E ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c Departement Klinische Forschung   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MICRORNA 125B; NUCLEAR FACTOR KAPPA B INHIBITOR INTERACTING RAS LIKE 2 PROTEIN; PROTEIN P53; TEMOZOLOMIDE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INDUCED PROTEIN 3; UNCLASSIFIED DRUG; DACARBAZINE; DNA BINDING PROTEIN; MICRORNA; MIRN125 MICRORNA, HUMAN; NUCLEAR PROTEIN; RAS PROTEIN; RNA; SIGNAL PEPTIDE; TNFAIP3 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CANCER SURVIVAL; CELL CYCLE ARREST; CONTROLLED STUDY; ENZYME ACTIVITY; GENE OVEREXPRESSION; GLIOBLASTOMA; HUMAN; HUMAN CELL; OVERALL SURVIVAL; PRIORITY JOURNAL; UPREGULATION; ANALOGS AND DERIVATIVES; DRUG RESISTANCE; GENETICS; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

APOPTOSIS; CELL LINE, TUMOR; DACARBAZINE; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; GLIOBLASTOMA; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICRORNAS; NUCLEAR PROTEINS; RAS PROTEINS; RNA, NEOPLASM;

EID: 84903771806     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.245     Document Type: Article

References (48)

1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007; 114: 97-109.
2. Mitchell PP, Ellison DWD. Mendelow ADA. Surgery for malignant gliomas: mechanistic reasoning and slippery statistics. Lancet Neurol 2005; 4: 10-10.
3. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJB, Janzer RC et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10: 459-466.
4. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000; 343: 1350-1354.
5. Hegi ME, Diserens A-C, Gorlia T, Hamou M-F, de Tribolet N, Weller M et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352: 997-1003.
6. Parsons DW, Jones S, Zhang X, JC-H Lin, Leary RJ, Angenendt P et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008; 321: 1807-1812.
7. SongTao QQ, Lei YY, Si GG, YanQing DD, HuiXia HH, XueLin ZZ et al. IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma. Cancer Sci 2012; 103: 269-273.
8. Weaver KD, Yeyeodu S, Cusack JC, Baldwin AS, Ewend MG. Potentiation of chemotherapeutic agents following antagonism of nuclear factor kappa B in human gliomas. J Neurooncol 2003; 61: 187-196.
9. Nagai S, Washiyama K, Kurimoto M, Takaku A, Endo S, Kumanishi T. Aberrant nuclear factor-kappaB activity and its participation in the growth of human malignant astrocytoma. J Neurosurg 2002; 96: 909-917.
10. Wang CYC, Cusack JCJ, Liu RR, Baldwin ASA. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat Med 1999; 5: 412-417.
11. Nakanishi C, Toi M. Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 2005; 5: 297-309.
12. Bredel M, Bredel C, Juric D, Duran GE, Yu RX, Harsh GR et al. Tumor necrosis factor-alpha-induced protein 3as a putative regulator of nuclear factor-kappaB-mediated resistance to O6-alkylating agents in human glioblastomas. J Clin Oncol 2006; 24: 274-287.
13. Shembade N, Ma A, Harhaj EW. Inhibition of NF-kappaB signaling by A20 through disruption of ubiquitin enzyme complexes. Science 2010; 327: 1135-1139.
14. Hymowitz SG, Wertz IE. A20: from ubiquitin editing to tumour suppression. Nat Rev Cancer 2010; 10: 332-341.
15. Fenwick C, Na SY, Voll RE, Zhong H, Im SY, Lee JW et al. A subclass of Ras proteins that regulate the degradation of IkappaB. Science 2000; 287: 869-873.
16. Tago K, Funakoshi-Tago M, Sakinawa M, Mizuno N, Itoh H. KappaB-Ras is a nuclearcytoplasmic small GTPase that inhibits NF-kappaB activation through the suppression of transcriptional activation of p65/RelA. J Biol Chem 2010; 285: 30622-30633.
17. Lin H, Wang Y, Zhang X, Liu B, Zhang W, Cheng J. Prognostic significance of kappaB-Ras1 expression in gliomas. Med Oncology 2012; 29: 1272-1279.
18. Chen Y, Vallee S, Wu J, Vu D, Sondek J, Ghosh G. Inhibition of NF-kappaB activity by IkappaBbeta in association with kappaB-Ras. Mol Cell Biol 2004; 24: 3048-3056.
19. Iorio MV, Croce CM. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med 2012; 4: 143-159.
20. Hwang H-WH, Mendell JTJ. MicroRNAs in cell proliferation, cell death, and tumorigenesis. Br J Cancer 2006; 94: 776-780.
21. Shi L, Zhang J, Pan T, Zhou J, Gong W, Liu N et al. MiR-125b is critical for the suppression of human U251 glioma stem cell proliferation. Brain Res 2010; 1312: 120-126.
22. Yu Y, Wan Y, Huang C. The biological functions of NF-kappaB1 (p50) and its potential as an anti-cancer target. Curr Cancer Drug Targets 2009; 9: 566-571.
23. Lavon I, Fuchs D, Zrihan D, Efroni G, Zelikovitch B, Fellig Y et al. Novel mechanism whereby nuclear factor kappaB mediates DNA damage repair through regulation of O(6)-methylguanine-DNA-methyltransferase. Cancer Res 2007; 67: 8952-8959.
24. Vassella E, Vajtai I, Bandi N, Arnold M, Kocher V, Mariani L. Primer extension based quantitative polymerase chain reaction reveals consistent differences in the methylation status of the MGMT promoter in diffusely infiltrating gliomas (WHO grade II-IV) of adults. J Neurooncol 2011; 104: 293-303.
25. Tili E, Michaille J-J, Croce CM. MicroRNAs play a central role in molecular dysfunctions linking inflammation with cancer. Immunol Rev 2013; 253: 167-184.
26. Sun Y-M, Lin K-Y, Chen Y-Q. Diverse functions of miR-125 family in different cell contexts. J Hematol Oncol 2013; 6: 6.
27. Zhang Y, Gao J-S, Tang X, Tucker LD, Quesenberry P, Rigoutsos I et al. MicroRNA 125a and its regulation of the p53 tumor suppressor gene. FEBS Lett 2009; 583: 3725-3730.
28. Xia H-F, He T-Z, Liu C-M, Cui Y, Song P-P, Jin X-H et al. MiR-125b expression affects the proliferation and apoptosis of human glioma cells by targeting Bmf. Cell Physiol Biochem 2009; 23: 347-358.
29. Murray MY, Rushworth SA, Zaitseva L, Bowles KM, Macewan DJ. Attenuation of dexamethasone-induced cell death in multiple myeloma is mediated by miR-125b expression. Cell Cycle 2013; 12: 2144-2153.
30. Shi X-B, Xue L, Yang J, Ma A-H, Zhao J, Xu M et al. An androgen-regulated miRNA suppresses Bak1 expression and induces androgen-independent growth of prostate cancer cells. Proc Natl Acad Sci USA 2007; 104: 19983-19988.
31. Gong J, Zhang J-P, Li B, Zeng C, You K, Chen M-X et al. MicroRNA-125b promotes apoptosis by regulating the expression of Mcl-1 Bcl-w and IL-6R. Oncogene 2013; 32: 3071-3079.
32. Willimott S, Wagner SD. miR-125b and miR-155 contribute to BCL2 repression and proliferation in response to CD40 ligand (CD154) in human leukemic B-cells. J Biol Chem 2012; 287: 2608-2617.
33. Zhao A, Zeng Q, Xie X, Zhou J, Yue W, Li Y et al. MicroRNA-125b induces cancer cell apoptosis through suppression of Bcl-2 expression. J Genet Genomics 2012; 39: 29-35.
34. Olarerin-George AO, Anton L, Hwang Y-C, Elovitz MA, Hogenesch JB. A functional genomics screen for microRNA regulators of NF-kappaB signaling. BMC Biol 2013; 11: 19-16.
35. Wu N, Lin X, Zhao X, Zheng L, Xiao L, Liu J et al. MiR-125b acts as an oncogene in glioblastoma cells and inhibits cell apoptosis through p53 and p38MAPK-independent pathways. Br J Cancer 2013; 109: 2853-2863.
36. Kim S-W, Ramasamy K, Bouamar H, Lin A-P, Jiang D, Aguiar RCT. MicroRNAs miR-125a andmiR-125b constitutively activate the NF-kB pathway by targeting the tumor necrosis factor alpha-induced protein 3 (TNFAIP3, A20). Proc Natl Acad Sci USA 2012; 109: 7865-7870.
37. Tan G, Niu J, Shi Y, Ouyang H, Wu Z-H. NF-kB-dependent microRNA-125b up-regulation promotes cell survival by targeting p38a upon ultraviolet radiation. J Biol Chem 2012; 287: 33036-33047.
38. Verstrepen L, Verhelst K, van Loo G, Carpentier I, Ley SC, Beyaert R. Expression, biological activities and mechanisms of action of A20 (TNFAIP3). Biochem Pharmacol 2010; 80: 2009-2020.
39. Stupp R, Hegi ME, Gilbert MR, Chakravarti A. Chemoradiotherapy in malignant glioma: standard of care and future directions. J Clin Oncol 2007; 25: 4127-4136.
40. Murphy AJ, Guyre PM, Pioli PA. Estradiol suppresses NF-kappa B activation through coordinated regulation of let-7a and miR-125b in primary human macrophages. J Immunol 2010; 184: 5029-5037.
41. Ishii N, Maier D, Merlo A, Tada M, Sawamura Y, Diserens AC et al. Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol 1999; 9: 469-479.
42. Wischhusen J, Naumann U, Ohgaki H, Rastinejad F, Weller M. CP-31398 a novel p53-stabilizing agent, induces p53-dependent and p53-independent glioma cell death. Oncogene 2003; 22: 8233-8245.
43. Bandi N, Zbinden S, Gugger M, Arnold M, Kocher V, Hasan L et al. miR-15a and miR-16 are implicated in cell cycle regulation in a Rb-dependent manner and are frequently deleted or down-regulated in non-small cell lung cancer. Cancer Res 2009; 69: 5553-5559.
44. Britschgi C, Jenal M, Rizzi M, Mueller BU, Torbett BE, Andres A-C et al. HIC1 tumour suppressor gene is suppressed in acute myeloid leukaemia and induced during granulocytic differentiation. Br J Haematol 2008; 141: 179-187.
45. Gautschi O, Tepper CG, Purnell PR, Izumiya Y, Evans CP, Green TP et al. Regulation of Id1 expression by SRC: implications for targeting of the bone morphogenetic protein pathway in cancer. Cancer Res 2008; 68: 2250-2258.
46. Linsley PSP, Schelter JJ, Burchard JJ, Kibukawa MM, Martin MMM, Bartz SRS et al. Transcripts targeted by the microRNA-16 family cooperatively regulate cell cycle progression. Mol Cell Biol 2007; 27: 2240-2252.
47. Gugger MM, Kappeler AA, Vonlanthen SS, Altermatt HJH, Ris HBH, Lardinois DD et al. Alterations of cell cycle regulators are less frequent in advanced non-small cell lung cancer than in resectable tumours. Lung Cancer 2001; 33: 229-239.
48. Korkolopoulou P, Levidou G, Saetta AA, El-Habr E, Eftichiadis C, Demenagas P et al. Expression of nuclear factor-kB in human astrocytomas: relation to pIkBa, vascular endothelial growth factor, Cox-2, microvascular characteristics, and survival. Hum Pathol 2008; 39: 1143-1152.